An experimental AstraZeneca (NASDAQ:AZN) drug, anselamimab, failed to extend survival or cut heart-related hospitalizations in patients with a rare plasma cell disorder, disappointing hopes it could ...

To meet that, ASML’s order intake needs to pick up significantly, so there are some short-term headwinds." Shares in MP ...

AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

Hong Kong-based Sino Biopharm, which took its stake in LaNova when it participated in the company's $42 million financing ...

Investing.com -- AstraZeneca’s (ST: AZN) rare disease unit Alexion (NASDAQ: ALXN) said its experimental drug anselamimab ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

AstraZeneca PLC on Wednesday announced that its antibody anselamimab did not achieve statistical significance in the overall patient population, thought it noted a "meaningful improvement" in ...

An investigational AstraZeneca treatment for amyloidosis has failed to show a statistical significance in late-stage trials, the blue chip pharmaceutical group said on Wednesday.

AstraZeneca said its amyloidosis treatment anselamimab failed to reach its primary goal in a final-stage trial.

AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for ...

AstraZeneca on Wednesday said that its experimental drug anselamimab did not meet the main goal of a late-stage study for the treatment of AL amyloidosis, a rare condition that causes a buildup of ...

True transformation requires AI that links customer data, knowledge bases, and operational systems to enable intelligent ...